Beyond Air (FRA:48L) ROCE % : -150.57% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Beyond Air ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Beyond Air's annualized ROCE % for the quarter that ended in Dec. 2023 was -150.57%.

Beyond Air ROCE % Historical Data

The historical data trend for Beyond Air's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beyond Air ROCE % Chart

Beyond Air Annual Data

Trend

Jun15

Jun16

Dec17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

ROCE %

Get a 7-Day Free Trial

-123.22

-151.45

-72.85

-70.69

-87.96

Beyond Air Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-79.88	-151.88	-107.77	-125.01	-150.57

Beyond Air ROCE % Calculation

Beyond Air's annualized ROCE % for the fiscal year that ended in Mar. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	-55.453	/	( ( (90.073 - 9.726)	+	(64.212 - 18.475) )	/ 2 )
	=	-55.453	/	( (80.347	+	45.737)	/ 2 )
	=	-55.453	/	63.042
	=	-87.96 %

Beyond Air's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-59.932	/	( ( (54.351 - 11.669)	+	(47.602 - 10.675) )	/ 2 )
	=	-59.932	/	( ( 42.682	+	36.927 )	/ 2 )
	=	-59.932	/	39.8045
	=	-150.57 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Beyond Air (FRA:48L) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Beyond Air ROCE % Related Terms

Thank you for viewing the detailed overview of Beyond Air's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Beyond Air (FRA:48L) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Beyond Air Inc (FRA:48L) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

XAIR:USA

Address

900 Stewart Avenue, Suite 301, Garden City, New York, NY, USA, 11530

Website

https://www.beyondair.net

Beyond Air Inc is a clinical-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.

Beyond Air (FRA:48L) Headlines

No Headlines